Nasal Polyp Removal (Polypectomy / FESS) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Nasal polyps are benign, teardrop-shaped, non-cancerous outgrowths of the inflamed mucosa lining the nasal passages and paranasal sinuses. They arise from chronic eosinophilic inflammation and are strongly associated with type-2 airway inflammation — the same immunological pathway that drives asthma and atopic dermatitis. Polyps affect approximately 1–4% of the general population and are significantly more prevalent in patients with asthma, allergic rhinitis, cystic fibrosis, and aspirin-exacerbated respiratory disease (Samter's triad).

When medical therapy fails to control symptoms or polyp burden, surgical removal is indicated. The current gold standard is functional endoscopic sinus surgery (FESS) — an endoscopic technique that removes polyps and opens the affected sinus ostia under direct vision, without external incisions. FESS addresses both the polyps themselves and the underlying sinus drainage obstruction that perpetuates recurrence.

Critically, surgery is rarely curative in isolation: nasal polyp disease is a chronic inflammatory condition. Post-operative maintenance therapy with topical nasal steroids — and, increasingly, injectable biologic therapies targeting the type-2 inflammatory cascade — is essential to delay or prevent recurrence.

Surgical polypectomy is indicated for nasal polyps arising in the context of several conditions:

• Chronic rhinosinusitis with nasal polyps (CRSwNP) — the most common indication; CRS lasting >12 weeks with bilateral nasal polyposis on endoscopy and/or CT, failing adequate medical therapy
• Samter's triad (aspirin-exacerbated respiratory disease, AERD) — the combination of nasal polyps, asthma, and sensitivity to aspirin/NSAIDs; particularly aggressive polyposis with high recurrence; biologic therapy (dupilumab) should accompany surgery
• Allergic fungal rhinosinusitis (AFRS) — hypersensitivity reaction to inhaled fungi causing eosinophilic mucin, nasal polyps, and expansile sinus disease; requires both surgical clearance and post-operative antifungal irrigation
• Cystic fibrosis-related polyposis — up to 40% of CF patients develop nasal polyps; surgery is often required repeatedly throughout life; CFTR modulator therapy (e.g., elexacaftor-tezacaftor-ivacaftor) reduces polyp recurrence
• Unilateral polyps — a unilateral nasal polyp (antrochoanal polyp) typically arises from the maxillary sinus and protrudes into the nasopharynx; surgery is curative in most cases; unilateral disease also requires histological examination to exclude malignancy

Surgery is recommended when medical therapy has been adequately trialled without sufficient benefit:

• Failed medical therapy — symptoms persist despite a minimum 3-month course of intranasal corticosteroid (INCS) spray and at least one course of systemic (oral) corticosteroids
• CT sinus staging — a pre-operative CT of the paranasal sinuses (Lund-Mackay score) documents disease extent, identifies anatomical variants relevant to surgical safety (e.g., Onodi cells, low-lying skull base, medialised orbit), and guides the surgical plan
• Symptom severity — significant nasal obstruction affecting sleep or daily function; anosmia (loss of smell) impairing quality of life; recurrent acute sinusitis; chronic headache or facial pressure attributed to sinus disease
• Asthma control — patients with concurrent asthma must have optimally controlled lower airway disease before elective sinonasal surgery; AERD patients should discontinue aspirin and NSAIDs and may require aspirin desensitisation after surgery
• Biologic therapy pre-assessment — patients with severe refractory CRSwNP may be candidates for pre-operative or post-operative biologic therapy (dupilumab, mepolizumab, omalizumab) to reduce surgical polyp burden or delay recurrence

Modern management of nasal polyp disease employs a step-wise approach combining medical and surgical strategies:

• Functional endoscopic sinus surgery (FESS) — the standard surgical procedure; using a rigid endoscope and microdebrider or forceps, the surgeon removes polypoid tissue and opens the natural ostia of the maxillary, ethmoid, frontal, and sphenoid sinuses as required; no external incisions; performed under general anaesthesia in 30–90 minutes depending on extent
• Extended FESS / Draf procedures — for frontal sinus disease refractory to standard FESS, the Draf IIa, IIb, or III (endoscopic modified Lothrop procedure) provides wide drainage of the frontal recess
• Simple polypectomy — avulsion of accessible polyps using a nasal snare without sinus surgery; appropriate for antrochoanal polyps or isolated accessible polyps; not appropriate for bilateral CRSwNP as it does not address underlying sinus obstruction
• In-office polypectomy with SINUWAVE or steroid-eluting implants — emerging office-based techniques for limited, accessible polyposis using a vibrating polypectomy device or biodegradable implants delivering local mometasone
• Biologic therapy (type-2 targeted) — dupilumab (anti-IL-4Rα), mepolizumab (anti-IL-5), benralizumab (anti-IL-5Rα), and omalizumab (anti-IgE) reduce polyp burden and symptoms significantly; approved as add-on therapy for severe refractory CRSwNP; some patients achieve near-complete clearance without surgery; cost-prohibitive for many patients without insurance coverage

FESS for nasal polyps provides reliable symptom relief:

• Nasal obstruction — improvement in >90% of patients; most describe complete resolution of blockage within weeks of surgery
• Restoration of smell (olfaction) — anosmia improves in 60–80% of patients; extent of recovery depends on duration and severity of pre-operative smell loss and inflammatory burden
• Reduction in sinusitis episodes — improved sinus drainage reduces the frequency and severity of acute bacterial sinusitis episodes requiring antibiotics
• Sleep improvement — relief of nasal obstruction typically improves sleep quality and reduces snoring
• Improved asthma control — treating the upper airway component of unified airway inflammation leads to measurable improvement in bronchial hyperresponsiveness and asthma symptom scores in 50–60% of asthmatic patients
• Better medication delivery — opening the sinus cavities dramatically improves penetration of post-operative topical nasal steroid sprays and irrigation solutions to disease sites

FESS is a safe procedure in experienced hands but the close proximity of critical anatomical structures mandates careful pre-operative planning and surgical technique:

• Bleeding and epistaxis — minor intra-operative bleeding is expected; significant post-operative epistaxis requiring intervention occurs in 1–2% of cases
• CSF leak (cerebrospinal fluid) — the skull base (cribriform plate and ethmoid roof) bounds the superior limits of the ethmoid sinuses; inadvertent breach causes CSF rhinorrhoea; incidence 0.1–0.3% in experienced hands; requires immediate recognition and repair
• Orbital injury — the lamina papyracea (thin orbital wall) separates the ethmoid sinuses from the orbit; violation causes periorbital haematoma, diplopia, or (very rarely) blindness due to optic nerve or vascular injury; incidence <0.1%
• Epiphora (watery eye) — damage to the nasolacrimal duct at the inferior extent of the uncinate process; rare with anatomical awareness
• Infection and synechia — post-operative adhesions (scar bands) between adjacent mucosal surfaces cause scarring that may require revision debridement; prevented by regular post-operative endoscopic debridement and irrigation
• Polyp recurrence — the most clinically significant long-term issue; 40–60% of CRSwNP patients have endoscopic recurrence within 5 years; AERD and allergic fungal sinusitis carry the highest recurrence risk; biologic therapy substantially reduces recurrence rates
• Hyposmia — rare worsening of smell post-operatively; most cases are temporary

Post-operative care is critical and significantly impacts long-term outcomes:

• Immediate recovery (Days 1–7) — nasal congestion, blood-tinged discharge, and crusting are expected; nasal packs may be placed intra-operatively and are removed at 24–48 hours if non-dissolvable; pain is usually mild and managed with paracetamol; avoid nose blowing for 5–7 days
• Saline nasal irrigation — large-volume (240 ml) high-pressure saline irrigation (Neti pot or squeeze bottle) initiated within 24–48 hours and continued twice daily for 4–8 weeks; critical for crust clearance and mucociliary recovery
• Topical nasal steroid sprays — high-dose mometasone or fluticasone furoate initiated after initial healing (usually week 2–3) and continued indefinitely as maintenance therapy to suppress inflammation and reduce recurrence risk
• Post-operative debridement — endoscopic clinic debridement at 1–2 weeks, 4–6 weeks, and 3 months removes crusts, adhesions, and residual polyp tissue; this follow-up care is as important as the surgery itself
• Return to work — most patients return to desk work within 5–7 days; avoid strenuous activity and nose blowing for 2 weeks
• Long-term surveillance — annual rhinological review is recommended; recurrence detected early can often be managed with short courses of oral steroids or biologic therapy without revision surgery

Costs for nasal polypectomy/FESS vary with disease extent and setting:

• Extent of surgery — unilateral limited polypectomy is less expensive than bilateral pan-sinus FESS; revision surgery after prior scar tissue formation increases operative complexity and cost
• Equipment — powered microdebrider and image guidance (CT-based navigation) systems increase theatre costs but improve safety and outcomes, particularly in revision cases or complex anatomy
• Country and facility — India $800–$2,500; Thailand $1,500–$4,000; Turkey $1,000–$3,000; UK (NHS): no cost to eligible patients; UK (private) £3,500–£7,000; USA $8,000–$20,000 with anaesthesia and facility fees
• Biologic therapy cost — dupilumab costs $30,000–$40,000 per year without insurance; mepolizumab approximately $25,000 per year; these costs are the most significant financial consideration for long-term disease management
• Post-operative supplies — saline irrigators, hypertonic rinse sachets, and nasal steroid prescriptions are ongoing but modest costs

The management of nasal polyp disease is evolving rapidly, with several non-surgical and minimally invasive options:

• Intranasal corticosteroid sprays (INCS) — mometasone furoate, fluticasone propionate, and budesonide are first-line medical therapy; evidence shows modest polyp size reduction but rarely achieve complete clearance of significant polyposis; safe for long-term use
• Systemic (oral) corticosteroids — short courses of prednisolone (20–40 mg for 5–10 days) rapidly shrink polyps and restore smell but cannot be used chronically due to systemic side effects; useful diagnostically and as a bridge
• Biologic therapy — dupilumab (IL-4Rα blocker) achieves >50% reduction in polyp score and symptom improvement in 70–80% of patients in RCTs; approved by FDA (2019) and EMA as add-on therapy for adults with severe uncontrolled CRSwNP; some patients achieve results comparable to surgery; suitable as an alternative to surgery in appropriate patients or as post-operative maintenance
• Saline irrigation — twice-daily large-volume saline irrigation reduces inflammatory mediator load, improves mucociliary clearance, and provides modest symptomatic relief; standard adjunct to all other therapies
• Aspirin desensitisation (for AERD) — following initial FESS, graduated oral aspirin challenge and desensitisation in a supervised setting significantly reduces recurrence rate in AERD and allows long-term aspirin therapy for cardiovascular benefit